The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
Abstract
OBJECTIVE: To estimate risk and relative risk (RR) of acute pancreatitis among patients using incretin-based diabetes therapies (exenatide or sitagliptin) compared to patients treated with agents with established safety profiles (metformin or glyburide). RESEARCH DESIGN AND METHODS: The study population was derived from a large US commercial health insurance transaction database using an active drug safety surveillance system (i3 Aperio). This analysis is based on data from June 2005 through June 2008. Cohorts of exenatide and sitagliptin initiators were each matched to an equal number of metformin or glyburide (met/gly) initiators using propensity scores to reduce confounding in the comparison of outcomes during follow-up. Patients with claims suggesting pancreatic disease in the 6 months prior to cohort entry were excluded. MAIN OUTCOME MEASURE: Claims for hospitalizations associated with a primary diagnosis of acute pancreatitis (ICD-9 577.0). RESULTS: There were 27 996 exenatide initiators and 16 276 sitagliptin initiators and approximately equal numbers of matched comparators. During follow-up of up to 1 year, acute pancreatitis occurred among 0.13% of patients treated with exenatide and 0.12% of patients treated with sitagliptin. The risk of acute pancreatitis was comparable for initiators of exenatide (RR 1.0; 95% confidence interval (CI) 0.6-1.7) and sitagliptin (RR 1.0; 95% CI 0.5-2.0) relative to the comparison cohorts. CONCLUSIONS: These data do not provide evidence for an association of acute pancreatitis among initiators of exenatide or sitagliptin compared to met/gly initiators. These results are limited by the data available in an administrative, healthcare database.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
The Effectiveness of Right Heart Catheterization in the Initial Care of Critically III Patients
Connors, A. F. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110043030 · Cited by 2,210
Reducing bias in a propensity score matched-pair sample using greedy matching techniques
Parsons, L. (2001) · Medical Entomology and Zoology · Cited by 733
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Estimating medication persistency using administrative claims data.
Sikka, R., Xia, F., & Aubert, R. E. (2005) · PubMed · Cited by 456
Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death
Schneeweiss, S., Seeger, J. D., Landon, J., & Walker, A. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707571 · Cited by 357
Self-citationDarkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271
Limitations and strengths of spontaneous reports data
Goldman, S. A. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80007-6 · Cited by 242
An application of propensity score matching using claims data
Seeger, J. D., Williams, P. L., & Walker, A. M. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1062 · Cited by 218
Self-citationBaldessarini, R., Henk, H., Sklar, A., Chang, J., & Leahy, L. (2008) · Psychiatric Services · doi:10.1176/appi.ps.59.10.1175 · Cited by 173
Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives
Seeger, J. D., Loughlin, J., Eng, P. M., Clifford, C. R., Cutone, J., & Walker, A. M. (2007) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000279448.62221.a8 · Cited by 158
Self-citationTextbook of Pharmacoepidemiology
Strom, B. L., Kimmel, S. E., & Hennessy, S. (2013) · Wiley eBooks · doi:10.1002/9781118344828 · Cited by 153
Studying Prescription Drug Use and Outcomes With Medicaid Claims Data
Crystal, S., Akıncıgil, A., Bilder, S. M., & Walkup, J. T. (2007) · Medical Care · doi:10.1097/mlr.0b013e31805371bf · Cited by 149
Exenatide (Exendin-4)–Induced Pancreatitis
Denker, P. S., & Dimarco, P. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-2043 · Cited by 140
Exenatide and rare adverse events.
Ahmad, S. R., & Swann, J. (2008) · PubMed · Cited by 122
Sclar, D. A., Chin, A., Skaer, T. L., Okamoto, M. P., Nakahiro, R. K., & Gill, M. A. (1991) · PubMed · Cited by 113
The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada
Walker, A. M., Szneke, P., Weatherby, L. B., DICKER, L. W., Lanza, L. L., Loughlin, J. E., Yee, C. L., & Dreyer, N. A. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00241-7 · Cited by 88
Textbook of Pharmacoepidemiology
Strom, B. L., & Kimmel, S. E. (2006) · Wiley eBooks · doi:10.1002/9781118707999 · Cited by 86
Rodgers, A. J., & MacMahon, S. W. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1653746 · Cited by 72
MILLER, D. P., Alfredson, T. D., Cook, S. F., Sands, B. E., & Walker, A. M. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07418.x · Cited by 61
Enger, C. L., Cali, C., & Walker, A. M. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.725 · Cited by 56
An evaluation of spontaneous adverse drug reaction monitoring systems.
Rm, S., & Ea, B. (1986) · PubMed · Cited by 56
Utility of a transdermal delivery system for antihypertensive therapy. Part 1
Sclar, D. A., Skaer, T. L., Chin, A., Okamoto, M. P., & Gill, M. A. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90063-4 · Cited by 41
Pattern recognition in health insurance claims databases
Walker, A. M. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.611 · Cited by 31
Yadav, D. K., & Dhir, R. (2006) · Pancreas · doi:10.1097/00006676-200611000-00240 · Cited by 25
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Metadata
- Authors
- Dore, D. D., Seeger, J. D., & Arnold Chan, K.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2009-03-12
- Volume
- 25
- Issue
- 4
- Pages
- 1019-1027
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W1970638723
- Cited by
- 326
- References
- 28
- FWCI
- 32.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.